Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 5, 2006, Pages 654-664

  Shiah, Her Shyong ^a   Chao, Yee ^a   Chen, Li Tzong ^a,b   Yao, Tzy Jyun ^c   Huang, Jin Ding ^c,d   Chang, Jang Yang ^a   Chen, Pei Jer ^e   Chuang, Tsai Rong ^a   Chin, Yung Hsin ^a   Whang Peng, Jacqueline ^a   Liu, Tsang Wu ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis inhibitor; Cirrhosis; Hepatitis virus; Maximum tolerated dose

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HEMOGLOBIN; LAXATIVE; THADO; THALIDOMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DYSPNEA; ESOPHAGUS VARICES BLEEDING; EXPERIENCE; FEMALE; FEVER; HAIR LOSS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NONLINEAR SYSTEM; PERIORBITAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SICK SINUS SYNDROME; SOMNOLENCE; STEADY STATE; VIRUS TITRATION;

EID: 84984535366     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0203-z     Document Type: Article

References (59)

1. Abramson N, Stokes PK, Luke M, Marks AR, Harris JM (2002) Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol 20:1147-1149
2. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF (2000) Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710-2717
3. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834
4. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407
5. Braun AG, Harding FA, Weinreb SL (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome p450. Toxicol Appl Pharmacol 82:175-179
6. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR, Chen LT (2004) Hepatocellular carcinoma with intra-atrial tumor thrombi: a report of three cases responsive to thalidomide treatment and literature review. Oncology 67:320-326
7. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J (2005) Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 22:217-226
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
9. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, Economou O, Anagnostopoulos N, Panayiotidis P (2001) Treatment of Waldestrom's macroglobulinemia with thalidomide. J Clin Oncol 19:3596-3601
10. Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117: 508-515
11. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA (2004) Thalidomide in cancer medicine. Ann Oncol 15:1151-1160
12. Eriksson T, Bjokman S, Fyge A, Ekberg H (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr 582:211-216
13. Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J, Scheffler M, Kaysen GA (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55:1701-1706
14. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E (2001) Randomized phase II study of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893
15. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E (1999) Pharmacokinetics of thalidomide in an elder prostate cancer population. J Pharm Sci 88:121-125
16. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715
17. Folkman J (1971) Tumor angiogenesis: therapeutic implication. N Engl J Med 285:1182-1186
18. Folkman J, Merler E, Abernathy C, William G (1971) Isolation of a tumor factor responsible or angiogenesis. J Exp Med 133:275-288
19. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61
20. Fowler R, Imrie K (2001) Thalidomide-associated hepatitis: a case report. Am J Hematol. 66:300-302
21. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O (1989) Treatment of refractory rheumatoid arthritis-the thalidomide experience. J Rheumatol 16:158-163
22. Habeck M (2003) Australia approves thalidomide. Lancet Oncol 4:713
23. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1:149-53
24. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL (2003) Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65:242-249
25. Huang JD, Chen RRL, Oie S (1984). Microfit: a Basic program for non-linear regression analysis of pharmacokinetic data using a microcomputer. J Taiwan Pharmaceutical Asso 36:69-81
26. Huupponen R, Pyykko K (1995) Stability of thalidomide in human plasma. Clin Chem 41(8 Pt 1):1199
27. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN (2002) Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 20:2610-2615
28. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H (1993) Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital substraction angiography. Hepatology 17:1003-1007
29. Kerbe RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13:31-36
30. Kong HL, Boyer MJ, Lim R, Clarke S, Millward MJ, Wong JE (2001) Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC): a Cancer Therapeutics Research Group (CTRG) study. Proc Am Soc Clin Oncol 20:133b
31. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461-466
32. Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 62:479-483
33. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock T, Levitt L (2002) Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 21:97b
34. Lin TM, Chen CJ, Tsai SF, Tsai TH (1988) Hepatoma in Taiwan. J Natl Public Health Assoc (ROC) 8:91-100
35. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R (2000) Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593-2602
36. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR (2001) Phase II study of thalidomide in the treatment of recurrenct glioblastoma multiforme. J Neurooncol 54:31-38
37. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M (1991) Benign and malignant nodules in cirrhotic liver: distinction based on blood supply. Radiology 78:493-497
38. McBride WG (1968) Thalidomide and congenital abnormalities. Lancet 2:1358
39. Merup M, Kutti J, Birgergard G, Mauritzson N, Bjorkholm M, Markevarn B, Maim C, Westin J, Palmblad J (2002) Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 19:79-86
40. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
41. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306
42. Nerenstone S, Friedman F (1987) Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 16:603-612
43. Okamoto E, Kyo A, Vamanaka N, Tanaka N, Kuwata K (1984) Prediction of the safe limits of hapatectomy by combined volumetric and functional measurement in patients with impaired hepatic function. Surgery 95:586-592
44. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328
45. Patt YZ, Hassan MM, Lozano RD, Ellis M, Peterson JA, Waugh KA (2000) Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23:319-322
46. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103:749-755
47. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965
48. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703
49. Schwartz JD, Sung MW, Lehrer D, Goldenberg A, Muggia F, Volm M (2002) Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-a upon disease progression. Proc Am Soc Clin Oncol 21:10b
50. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
51. Steins MB, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner T, Berdel WE, Mesters RM (2002) Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99:834-839
52. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol 14:140-147
53. Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD (2001) Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol 41:662-667
54. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:2364-2373
55. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK (2004) Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10:649-653
56. Weidner N, Semple J, Welch W, Folkman J (1991) Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. N Engl J Med 324:1-8
57. Wettstein AR, Meagher AP (1997) Thalidomide in Crohn's disease. Lancet 350:1445-1446
58. WHO technical report series (1983) Prevention of Liver Cancer. World Health Organization, Geneva
59. Xia JL, Yang BH, Tang ZY, Sun FX, Xue O, Gao DM (1997) Inhitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastases in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 123:383-387